Share this article
Share this article
BC Cancer, CPHIN and Roche Canada will co-create an evidence-generating framework to leverage real-world data and facilitate cost-effective access to targeted treatments for cancer patients
MISSISSAUGA, ON, May 28, 2021 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce a joint initiative with BC Cancer and the Canadian Personalized Healthcare Innovation Network (CPHIN) to co-create a real-world evidence (RWE) framework in British Columbia known as the PRecision Oncology
Evidence
Cancer
Treatment (PREDiCT). The PREDiCT initiative will generate and assess RWE, which may be used to help shape new sustainable reimbursement pathways for personalized cancer treatments.